莫西沙星與左氧氟沙星治療copd加重期療效與安全性的meta分析.doc
約8頁(yè)DOC格式手機(jī)打開(kāi)展開(kāi)
莫西沙星與左氧氟沙星治療copd加重期療效與安全性的meta分析,莫西沙星與左氧氟沙星治療copd加重期療效與安全性的meta分析摘要：通過(guò)系統(tǒng)評(píng)價(jià)莫西沙星（moxifloxacin）與左氧氟沙星（levofloxacin）。比較二者在治療慢性阻塞性肺疾?。╟opd）加重期的臨床療效和安全性。為臨床應(yīng)用提供更優(yōu)化的方案。計(jì)算機(jī)檢索cnki、wanfang data、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)...
內(nèi)容介紹
此文檔由會(huì)員 一切如愿8 發(fā)布
莫西沙星與左氧氟沙星治療COPD加重期療效與安全性的Meta分析
摘要：通過(guò)系統(tǒng)評(píng)價(jià)莫西沙星（moxifloxacin）與左氧氟沙星（levofloxacin）。比較二者在治療慢性阻塞性肺疾病（COPD）加重期的臨床療效和安全性。為臨床應(yīng)用提供更優(yōu)化的方案。計(jì)算機(jī)檢索CNKI、WanFang Data、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)。檢索時(shí)間為2000年至2012年。收集比較moxifloxacin與levofloxacin治療COPD加重期的RCT。剔除不符合要求的文獻(xiàn)后，使用RevMan5.0軟件進(jìn)行Meta分析。共納入7個(gè)RCT，共計(jì)409例COPD患者。Meta分析結(jié)果顯示：在總有效率方面，莫西沙星高于左氧氟沙星[OR=2.79，95%Cl（1.56,5.01），P=0.0006]；在細(xì)菌清除率方面，moxifloxacin也顯著高于levofloxacin [OR=2.27，95%Cl（1.23,4.19），P=0.009]。409例患者中，moxifloxacin的不良反應(yīng)共發(fā)生了13例，而levofloxacin的發(fā)生了22例。moxifloxacin的總有效率與細(xì)菌清除率均顯著高于levofloxacin。而且moxifloxacin的不良反應(yīng)發(fā)生數(shù)較少。因此可以考慮釆用莫西沙星來(lái)代替左氧氟沙星用于COPD加重期的治療。
關(guān)鍵詞：莫西沙星；左氧氟沙星；COPD；Meta分析；
Meta-analysis of moxifloxacin and levofloxacin in the treatment of COPD exacerbations of efficacy and safety
Abstract:To assess the clinically effectiveness and safety of moxifloxacin versus levofloxacin for the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Provides a more optimal solution for clinical applications.Such databases as CNK,WanFang Data and Chinese Biomedical Literature Database were electronically searched.The search time was 2000 to 2012. After removing non-compliant literature, a meta-analysis using the software RevMan5.0, collection compared to the treatment of levofloxacin and moxifloxacin of COPD exacerbation Of RCT. Total of seven trials, a total of 409 patients with human patients with COPD.The results of meta-analysis showed that ,to efficiency ,moxifloxacin group was significantly superior to levofloxacin group [OR=2.79,95%Cl（1.56,5.01）,P=0.0006].Clearance rate of bacteria,Tmoxifloxacin was also significantly higher than levofloxacin [OR = 2.27, 95% CI (1.23,4.19), P = 0.009].A total of 409 patients, the adverse reactions of moxifloxacin group has 13 cases and the levofloxacin group has 22 cases. To improve the clearance rate of bacteria and efficiency, moxifloxacin is superior to reduce the side effects of treatment of AECOPD, to levofloxacin.Hence it is considerable to use moxifloxacin instead oflevonoxacin in the treatment of AECOPD if necessary.
Keywords: Moxifloxacin;Levofloxacin;COPD;Meta-analysis
摘要：通過(guò)系統(tǒng)評(píng)價(jià)莫西沙星（moxifloxacin）與左氧氟沙星（levofloxacin）。比較二者在治療慢性阻塞性肺疾病（COPD）加重期的臨床療效和安全性。為臨床應(yīng)用提供更優(yōu)化的方案。計(jì)算機(jī)檢索CNKI、WanFang Data、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)。檢索時(shí)間為2000年至2012年。收集比較moxifloxacin與levofloxacin治療COPD加重期的RCT。剔除不符合要求的文獻(xiàn)后，使用RevMan5.0軟件進(jìn)行Meta分析。共納入7個(gè)RCT，共計(jì)409例COPD患者。Meta分析結(jié)果顯示：在總有效率方面，莫西沙星高于左氧氟沙星[OR=2.79，95%Cl（1.56,5.01），P=0.0006]；在細(xì)菌清除率方面，moxifloxacin也顯著高于levofloxacin [OR=2.27，95%Cl（1.23,4.19），P=0.009]。409例患者中，moxifloxacin的不良反應(yīng)共發(fā)生了13例，而levofloxacin的發(fā)生了22例。moxifloxacin的總有效率與細(xì)菌清除率均顯著高于levofloxacin。而且moxifloxacin的不良反應(yīng)發(fā)生數(shù)較少。因此可以考慮釆用莫西沙星來(lái)代替左氧氟沙星用于COPD加重期的治療。
關(guān)鍵詞：莫西沙星；左氧氟沙星；COPD；Meta分析；
Meta-analysis of moxifloxacin and levofloxacin in the treatment of COPD exacerbations of efficacy and safety
Abstract:To assess the clinically effectiveness and safety of moxifloxacin versus levofloxacin for the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Provides a more optimal solution for clinical applications.Such databases as CNK,WanFang Data and Chinese Biomedical Literature Database were electronically searched.The search time was 2000 to 2012. After removing non-compliant literature, a meta-analysis using the software RevMan5.0, collection compared to the treatment of levofloxacin and moxifloxacin of COPD exacerbation Of RCT. Total of seven trials, a total of 409 patients with human patients with COPD.The results of meta-analysis showed that ,to efficiency ,moxifloxacin group was significantly superior to levofloxacin group [OR=2.79,95%Cl（1.56,5.01）,P=0.0006].Clearance rate of bacteria,Tmoxifloxacin was also significantly higher than levofloxacin [OR = 2.27, 95% CI (1.23,4.19), P = 0.009].A total of 409 patients, the adverse reactions of moxifloxacin group has 13 cases and the levofloxacin group has 22 cases. To improve the clearance rate of bacteria and efficiency, moxifloxacin is superior to reduce the side effects of treatment of AECOPD, to levofloxacin.Hence it is considerable to use moxifloxacin instead oflevonoxacin in the treatment of AECOPD if necessary.
Keywords: Moxifloxacin;Levofloxacin;COPD;Meta-analysis
